A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Clinical trial NCT02129075 · COMPLETED

Trial details

NCT number: NCT02129075
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cutaneous Melanoma Melanoma Melanoma of Unknown Primary Mucosal Melanoma Ocular Melanoma Stage IIB Cutaneous Melanoma AJCC v6 and v7 Stage IIC Cutaneous Melanoma AJCC v6 and v7 Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7

Start date: 2014-04-09
Primary completion: 2016-03-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.